| Gene symbol | KRAS | Synonyms | C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras, K-Ras 2, KI-RAS, KRAS1, KRAS2, NS, NS3, OES, RALD, RASK2, c-Ki-ras, c-Ki-ras2 | Type of gene | protein-coding |
| Chromosome | 12 | Map location | 12p12.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | KRAS proto-oncogene, GTPase | ||||
| GTO ID | GTC0962 |
| Trial ID | ChiCTR2100054460 |
| Disease | Pancreatic Cancer |
| Altered gene | KRAS |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | KRAS G12V TCR-T cells |
| HLA | HLA-A*11:01 |
| Phase | Early_Phase1 |
| Recruitment status | Recruiting |
| Title | A clinical trial study for evaluating the efficacy of KRAS-mutated antigen-specific TCR T cell therapy for advanced pancreatic cancer |
| Year | 2021 |
| Country | China |
| Company sponsor | Jinling Hospital Affiliated to Nanjing University (Eastern Theater General Hospital) |
| Cohort 1 | |||||||||
|
|||||||||